Evidence map›Paper›PMID 38767685›Full record

ArticleInvestigational new drugs2024

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H Miller, Aaron R Hansen, Jong-Seok Lee, Frank Tsai, Benjamin J Solomon, Tae Min Kim and 7 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Research Progress of Neutrophil Extracellular Traps in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Andrew J ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, 27710, USA. andrew.armstrong@duke.edu.ORCID http://orcid.org/0000-0001-7012-1754
Ravit GevaDivision of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hyun Cheol ChungYonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
Charlotte LemechScientia Clinical Research, Randwick, NSW, Australia.
Wilson H MillerSegal Cancer Center, McGill University, Jewish General Hospital, Montreal, QC, Canada.
Aaron R HansenPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Jong-Seok LeeSeoul National University Bundang Hospital, Gyeonggi-Do, South Korea.
Frank TsaiHonor Health, Scottsdale, AZ, USA.
Benjamin J SolomonPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Tae Min KimSeoul National University Hospital, Seoul, South Korea.ORCID http://orcid.org/0000-0001-6145-4426
Christian RolfoCenter for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Vincent GirandaMerck & Co., Inc, Rahway, NJ, USA.
Yixin RenMerck & Co., Inc, Rahway, NJ, USA.
Fang LiuMerck & Co., Inc, Rahway, NJ, USA.
Bhargava KandalaMerck & Co., Inc, Rahway, NJ, USA.ORCID http://orcid.org/0000-0001-5466-0897
Tomoko FreshwaterMerck & Co., Inc, Rahway, NJ, USA.
Judy S WangFlorida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38767685
PMCPMC11164789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.